Literature DB >> 19498420

Pharmacological and immunochemical characterization of alpha2* nicotinic acetylcholine receptors (nAChRs) in mouse brain.

Paul Whiteaker1, Jennifer A Wilking, Robert W B Brown, Robert J Brennan, Allan C Collins, Jon M Lindstrom, Jim Boulter.   

Abstract

AIM: alpha2 nAChR subunit mRNA expression in mice is most intense in the olfactory bulbs and interpeduncular nucleus. We aimed to investigate the properties of alpha2* nAChRs in these mouse brain regions.
METHODS: alpha2 nAChR subunit-null mutant mice were engineered. Pharmacological and immunoprecipitation studies were used to determine the composition of alpha2 subunit-containing (alpha2*) nAChRs in these two regions.
RESULTS: [(125)I]Epibatidine (200 pmol/L) autoradiography and saturation binding demonstrated that alpha2 deletion reduces nAChR expression in both olfactory bulbs and interpeduncular nucleus (by 4.8+/-1.7 and 92+/-26 fmol mg(-1) protein, respectively). Pharmacological characterization using the beta2-selective drug A85380 to inhibit [(125)I]epibatidine binding proved inconclusive, so immunoprecipitation methods were used to further characterize alpha2* nAChRs. Protocols were established to immunoprecipitate beta2 and beta4 nAChRs. Immunoprecipitation specificity was ascertained using tissue from beta2- and beta4-null mutant mice, and efficacy was good (>90% of beta2* and >80% of beta4* nAChRs were routinely recovered).
CONCLUSION: Immunoprecipitation experiments indicated that interpeduncular nucleus alpha2* nAChRs predominantly contain beta2 subunits, while those in olfactory bulbs contain mainly beta4 subunits. In addition, the immunoprecipitation evidence indicated that both nuclei, but especially the interpeduncular nucleus, express nAChR complexes containing both beta2 and beta4 subunits.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498420      PMCID: PMC4002370          DOI: 10.1038/aps.2009.68

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  25 in total

1.  Functional properties of human nicotinic AChRs expressed by IMR-32 neuroblastoma cells resemble those of alpha3beta4 AChRs expressed in permanently transfected HEK cells.

Authors:  M E Nelson; F Wang; A Kuryatov; C H Choi; V Gerzanich; J Lindstrom
Journal:  J Gen Physiol       Date:  2001-11       Impact factor: 4.086

2.  Involvement of the alpha3 subunit in central nicotinic binding populations.

Authors:  Paul Whiteaker; Cyrus G Peterson; Wei Xu; J Michael McIntosh; Richard Paylor; Arthur L Beaudet; Allan C Collins; Michael J Marks
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

3.  Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine.

Authors:  P Whiteaker; M Jimenez; J M McIntosh; A C Collins; M J Marks
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

4.  Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release.

Authors:  Sharon R Grady; Milena Moretti; Michele Zoli; Michael J Marks; Alessio Zanardi; Luca Pucci; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

5.  Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat.

Authors:  E Wada; K Wada; J Boulter; E Deneris; S Heinemann; J Patrick; L W Swanson
Journal:  J Comp Neurol       Date:  1989-06-08       Impact factor: 3.215

6.  The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells.

Authors:  Yingxian Xiao; Kenneth J Kellar
Journal:  J Pharmacol Exp Ther       Date:  2004-03-11       Impact factor: 4.030

7.  Functional expression of a new pharmacological subtype of brain nicotinic acetylcholine receptor.

Authors:  K Wada; M Ballivet; J Boulter; J Connolly; E Wada; E S Deneris; L W Swanson; S Heinemann; J Patrick
Journal:  Science       Date:  1988-04-15       Impact factor: 47.728

8.  Rat nicotinic acetylcholine receptor alpha2beta2 channels: comparison of functional properties with alpha4beta2 channels in Xenopus oocytes.

Authors:  S S Khiroug; L Khiroug; J L Yakel
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

9.  Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors.

Authors:  Mark E Nelson; Alexander Kuryatov; Catherine H Choi; Yan Zhou; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2003-02       Impact factor: 4.436

10.  Genes expressed in the brain define three distinct neuronal nicotinic acetylcholine receptors.

Authors:  P Nef; C Oneyser; C Alliod; S Couturier; M Ballivet
Journal:  EMBO J       Date:  1988-03       Impact factor: 11.598

View more
  16 in total

Review 1.  Enhanced Sensory-Cognitive Processing by Activation of Nicotinic Acetylcholine Receptors.

Authors:  Susan M Gil; Raju Metherate
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

2.  Differential expression of the beta4 neuronal nicotinic receptor subunit affects tolerance development and nicotinic binding sites following chronic nicotine treatment.

Authors:  Erin E Meyers; Esteban C Loetz; Michael J Marks
Journal:  Pharmacol Biochem Behav       Date:  2015-01-03       Impact factor: 3.533

3.  An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants.

Authors:  Christopher G Baddick; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2011-05-10       Impact factor: 5.858

4.  Human brain imaging of nicotinic acetylcholine α4β2* receptors using [18 F]Nifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways.

Authors:  Jogeshwar Mukherjee; Patrick J Lao; Tobey J Betthauser; Gurleen K Samra; Min-Liang Pan; Ishani H Patel; Christopher Liang; Raju Metherate; Bradley T Christian
Journal:  J Comp Neurol       Date:  2017-09-19       Impact factor: 3.215

5.  Cholinergic modulation of neuronal excitability in the accessory olfactory bulb.

Authors:  Richard S Smith; Ricardo C Araneda
Journal:  J Neurophysiol       Date:  2010-09-22       Impact factor: 2.714

6.  Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.

Authors:  D B Timmermann; K Sandager-Nielsen; T Dyhring; M Smith; A-M Jacobsen; E Ø Nielsen; M Grunnet; J K Christensen; D Peters; K Kohlhaas; G M Olsen; P K Ahring
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

7.  A signal peptide missense mutation associated with nicotine dependence alters α2*-nicotinic acetylcholine receptor function.

Authors:  Bhagirathi Dash; Ronald J Lukas; Ming D Li
Journal:  Neuropharmacology       Date:  2014-01-24       Impact factor: 5.250

8.  The unique α4+/-α4 agonist binding site in (α4)3(β2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (α4)2(β2)3 subtype.

Authors:  J Brek Eaton; Linda M Lucero; Harrison Stratton; Yongchang Chang; John F Cooper; Jon M Lindstrom; Ronald J Lukas; Paul Whiteaker
Journal:  J Pharmacol Exp Ther       Date:  2013-11-04       Impact factor: 4.030

9.  α-Conotoxins Identify the α3β4* Subtype as the Predominant Nicotinic Acetylcholine Receptor Expressed in Human Adrenal Chromaffin Cells.

Authors:  Arik J Hone; J Michael McIntosh; Layla Azam; Jon Lindstrom; Linda Lucero; Paul Whiteaker; Juan Passas; Jesús Blázquez; Almudena Albillos
Journal:  Mol Pharmacol       Date:  2015-09-01       Impact factor: 4.436

10.  Retrograde inhibition by a specific subset of interpeduncular α5 nicotinic neurons regulates nicotine preference.

Authors:  Jessica L Ables; Andreas Görlich; Beatriz Antolin-Fontes; Cuidong Wang; Sylvia M Lipford; Michael H Riad; Jing Ren; Fei Hu; Minmin Luo; Paul J Kenny; Nathaniel Heintz; Ines Ibañez-Tallon
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.